Accipiter Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AT&T
T
|
+$6.65M |
| 2 |
CVS Health
CVS
|
+$6.59M |
| 3 |
WBA
Walgreens Boots Alliance
WBA
|
+$6.44M |
| 4 |
Cigna
CI
|
+$2.6M |
| 5 |
Service Corp International
SCI
|
+$926K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$12M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$970K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 10.26% |
| 2 | Healthcare | 7.59% |
| 3 | Communication Services | 2.09% |
| 4 | Consumer Discretionary | 0.29% |
Similar funds
Accipiter Capital Management's Q2 2018 Portfolio in Review
As of Q2 2018, Accipiter Capital Management held 9 positions worth $308M, up 550% from $47.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Accipiter Capital Management deployed $229M of net new capital in Q2 2018, opening 5 new positions and adding to 2 existing holdings. Its largest new stake was AT&T: 264,800 shares worth $6.42M.
By sector, the portfolio is most concentrated in Energy at 10% of assets, down from 57% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $970K trimmed.
- Accipiter Capital Management's largest Q2 2018 buy was AT&T: 264,800 shares worth $6.42M.
- Accipiter Capital Management added most to Cigna in Q2 2018, an estimated $2.6M increase.
- Accipiter Capital Management's biggest Q2 2018 reduction was Teva Pharmaceuticals, cutting an estimated $970K.
- Accipiter Capital Management fully exited Shire pic in Q2 2018, selling an estimated $12M.
- Accipiter Capital Management's ten largest holdings make up 100% of its $308M portfolio in Q2 2018.
- Accipiter Capital Management opened 5 new positions and closed 1 in Q2 2018.
- Accipiter Capital Management's portfolio value rose 550% quarter-over-quarter to $308M.
Based on Accipiter Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.